P
115.42
10.75 (10.27%)
| Previous Close | 104.67 |
| Open | 107.74 |
| Volume | 562,640 |
| Avg. Volume (3M) | 239,077 |
| Market Cap | 1,655,451,008 |
| Price / Book | 6.95 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.08 |
| Total Debt/Equity (MRQ) | 23.67% |
| Current Ratio (MRQ) | 8.84 |
| Operating Cash Flow (TTM) | -16.51 M |
| Levered Free Cash Flow (TTM) | -5.43 M |
| Return on Assets (TTM) | -18.40% |
| Return on Equity (TTM) | -89.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Palvella Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 22.87% |
| % Held by Institutions | 47.68% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |